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A B S T R A C T
The present work reports the isolation, characterization and the complete sequence of a phospholipase A2 (PLA2)
present in the skin secretion of Pithecopus azureus. Among several peptides and small proteins previously de-
scribed by our group from some species belonging to this amphibian genus (formerly named Phyllomedusa), a
15 kDa N-glycosylated protein showing PLA2 activity was puriﬁed, assayed, sequenced and named Pa-PLA2. The
Pithecopus azureus skin phospholipase A2 polypeptide chain is composed by 125 amino acid residues linked by
seven disulﬁde bonds and two N-glycosylated sites (N67 and N108). The Pa-PLA2 enzymatic activity was qua-
litatively evaluated and compared to classical viperid PLA2 showing that both, native and deglycosylated Pa-
PLA2 forms, are catalytically functional. The tridimensional molecular model of Pa-PLA2 indicates that the
observed glycan moieties are suggestively placed far from the active site of that enzyme and therefore having
little or no signiﬁcant role on the direct interaction of the Pa-PLA2 catalytic pocket and its substrates.
1. Introduction
Physiological and morphological adaptations are commonly en-
countered in amphibians, mostly linked to species-speciﬁc surviving
mechanisms and behavioral strategies such as mimicry, aposematism
and camouﬂage (Duellman and Trueb, 1994; Erspamer and Vialli,
1951). Given the natural hostilities of the biological contexts in which
they are inserted, amphibians are also equipped with a distinct defen-
sive machinery fostered by a glandular system responsible for the ac-
cumulation and/or synthesis of secretions rich in various types of al-
kaloids, biogenic amines, peptides and proteins (König et al., 2015,
2013; Toledo and Jared, 1995). The release of the amphibian's noxious
glandular content induced by predators or any other kind of biotic
stress is believed to be one of the major features responsible for their
evolutionary success (Batista et al., 1999; Brand et al., 2002; König
et al., 2015; Toledo and Jared, 1995).
Therefore, the molecular composition of amphibian's cutaneous
secretions has been the subject of numerous reports for decades. It is
noticeable that the large majority of these studies focuses on the
structural and functional characterization of peptides and secondary
metabolites (Brand et al., 2006, 2002; Conlon et al., 2009; Leite et al.,
2005; Magalhães et al., 2013; Prates et al., 2004; Resende et al., 2008;
Rollins-Smith and Conlon, 2005; Taboada et al., 2017; Wegener et al.,
1999). Conversely, much less information is available on higher mo-
lecular mass proteins, enzymes (Darby et al., 1991; Libério et al., 2014;
Mizuno et al., 1987; Resnick et al., 1991) and enzymatic inhibitors
(Darby et al., 1991; König et al., 2013; Zhang et al., 2010; Zhao et al.,
2005). Nevertheless, regarding these molecules, it is known that some
enzymes were found to be involved in the processing of precursor
peptides into mature molecules, catalysis of diﬀerent post-translational
modiﬁcations (König et al., 2015) and inactivation of mature peptides
after release onto the skin, in order to protect the animal from harmful
exposure of their own toxic molecules (Giovannini et al., 1987; König
et al., 2013).
Additionally, phospholipase A2 (PLA2), one of the most abundant
and studied enzymes present in snake venoms has also been detected in
the cutaneous secretion of amphibians and, in particular, PLA2 activity
in the crude extract of some species belonging to the Phyllomedusa
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genus such as P. tarsius, P. bicolor (Martins et al., 2007) and P. hy-
pochondrialis (Conceição et al., 2007) were reported.
Phospholipases, particularly the secretory forms of PLA2 (sPLA2),
are generally one of the major components of vertebrate and in-
vertebrate venoms (Davidson and Dennis, 1990; Heinrikson et al.,
1977; Lai and Her, 2000; Lomonte et al., 2003; Mukherjee, 2014; Owen
et al., 1990; Stanley, 2006). These molecules are typically constituted
by a single polypeptide chain internally stabilized by 6–8 disulﬁde
bonds (Burke and Dennis, 2009; Saikia et al., 2011; Sobrinho et al.,
2017), with molecular masses ranging from 14 to 18 kDa. Phospholi-
pases A2 belong to a superfamily of enzymes that catalyze the hydro-
lysis of fatty acids at the sn-2 position of phospholipids, by means of the
His/Asp dyad at the active site, in a calcium-dependent reaction (Bergh
et al., 1988; Dennis et al., 2011; Han et al., 1997; Hou et al., 2017;
Saikia et al., 2011; Schaloske and Dennis, 2006; Verheij et al., 1980;
Zhao et al., 2000).
These enzymes have been described to display other roles in a wider
biological scenario, although their more speciﬁc functions may diﬀer
from one group or subgroup to another. In general, their activities in-
clude maintenance of cellular phospholipids, generation of pros-
taglandins, thromboxanes and leukotrienes during inﬂammatory pro-
cesses (Burke and Dennis, 2009), antibacterial action against Gram-
positive and Gram-negative bacteria (Grönroos et al., 2001; Harwig
et al., 1995; Weinrauch et al., 1996) and antiviral activity (Fenard et al.,
2001; Kim et al., 2007; Mitsuishi et al., 2006).
The present work reports the unequivocally detection, puriﬁcation,
characterization, complete cDNA and amino acid sequences of a gly-
cosylated Phospholipase A2, named Pa-PLA2, isolated from the skin
secretion of Pithecopus azureus, previously designated as Phyllomedusa
azurea. Furthermore, in order to contribute to an initial understanding
on the possible cutaneous role(s) of Pa-PLA2, we have also provided
here a set of preliminary studies on the structural-functional features of
this molecule.
2. Experimental section
2.1. Animal capture and extraction of cutaneous secretion
Adult specimens of Pithecopus azureus were captured in Mimoso -
Goiás, authorized by the legal Ethics Committee on Animal Use (Nº
013/2015) and by the Instituto Chico Mendes de Conservação da
Biodiversidade (N°63740-1). The extraction of the cutaneous secretion
was performed using 6 V pulsed electrical stimulation, during 30 s at
the dorsal part of each specimen. Once obtained, the secretion was
immediately ﬁltered, frozen in liquid nitrogen and lyophilized.
2.2. Isolation of Pa-PLA2
Aliquots of about 2mg of the lyophilized crude extract were solu-
bilized in 500 μL of a TFA 0.1% (v/v) solution (solvent A) and frac-
tionated by Reversed-Phase High-Performance Liquid Chromatography
– RP-HPLC (Shimadzu Corporation, Japan) using a Jupiter 4μ Proteo,
(C18, 90Å, 250×10ID mm - Phenomenex) semi-preparative column.
Fractions were eluted by using a linear acetonitrile gradient ranging
from 5 to 65% (solvent B; containing TFA 0.1%), during 55min at a
ﬂow rate of 2.5mL/min. Fractions presenting PLA2 activity were sub-
mitted to additional chromatographic procedures using both analytical
reverse phase columns Aeris Widepore (3.6μ XB-C18 250×4.6ID mm –
Phenomenex) and SOURCE 5RPC-ST (4.6/150mm – GE) by applying
optimized solvent B gradients. PLA2 elution during all steps was mon-
itored at 216 and 280 nm and the respective chromatographic fractions
were manually collected and freeze-dried using a vacuum concentrator
(SpeedVac, Labconco). MALDI-TOF-MS mass analyses and purity eva-
luations were performed throughout the role process.
2.3. Sample preparation for structural analysis
The Pa-PLA2 fraction solubilized in 50 μL (1 μg/μL) of 50mM am-
monium bicarbonate buﬀer (pH 8.0) was submitted to reduction and S-
alkylation protocol using dithiothreitol (DDT) (100mM) and iodoace-
tamide (IAA) (300mM) fresh solutions during 30min at 60 °C and
30min in dark at room temperature, respectively. The resulting dena-
tured/alkylated sample was fractioned by RP-HPLC using analytical
column Vydac (5μ C18 4.6× 250mm – DIONEX) as previously de-
scribed using optimized solvent B gradient. Following the MALDI-TOF-
MS and ESI-MS analyses, denatured/alkylated Pa-PLA2 was submitted
to proteolysis using sequencing grade Trypsin (Sigma) in ammonium
bicarbonate buﬀer 50mM at 37 °C for 24 h. When necessary, RapiGest
SF (Waters) solution was used according to the manufacturer's in-
structions. Pa-PLA2 tryptic peptides were mass analyzed and sequenced
using both MALDI-TOF-MS/MS and nano LC-MS/MS methodologies.
2.4. Mass spectrometry MALDI-TOF/MS
MALDI-TOF/MS and MS/MS analyses were performed in an
UltraﬂeXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics,
Bremen – Germany). Samples were applied onto a MALDI target plate
after mixing 1:3 (v/v) with a saturated solution of α-cyano-4-hydro-
xycinnamic acid (CHCA). MS spectra were collected in linear or re-
ﬂector positive modes.
Intact Pa-PLA2 was partially sequenced by In-Source Decay (ISD)
fragmentation methods after sample mixing 1:6 (v/v) with a saturated
solution of 1,5-diaminonaftaleno (DAN) and application onto a MALDI
target plate. De novo sequencing of Pa-PLA2 tryptic peptides was ob-
tained by manual assignment and interpretation of the MS/MS spectra
acquired in LIFT™ mode. All spectra were processed and analyzed using
FlexAnalysis software 3.4 (Bruker Daltonics, Bremen – Germany).
2.5. Mass spectrometry ESI-Q-TOF/MS
The molecular mass evaluations of both glycosylated and deglyco-
sylated Pa-PLA2 were obtained by direct infusion of sample recon-
stituted in 1:1 acetonitrile:water containing 0.1% (by volume) formic
acid (FA). All mass analyses were conducted in positive ion mode using
an Impact II™mass spectrometry (Bruker Daltonics, Bremen - Germany)
controlled by Bruker otofControl software. Analysis time was 3min (per
sample) and spectra were collected using an optimized method for high
mass compounds with m/z range between 100 and 2500. Software
Compass DataAnalysis 4.3.110 (Bruker Daltonics, Bremen – Germany)
was used to process and analyze the obtained data.
2.6. NanoLC-MS/MS acquisition
Pa-PLA2 tryptic peptides solubilized in 10 μL of a FA 0.1% (v/v)
solution (solvent A) were fractionated by Reversed-Phase High-
Performed Liquid Chromatography – RP-HPLC using a nanoACQUITY™
system (Waters Corp., USA) equipped with a Symmetry (C18, 5 μm,
5mm×300 μm) pre-column and a HSST3 (C18, 1.8 μm,
75 μm×150mm analytical column (Waters Corp., Manchester, UK).
Fractions were eluted by using a gradient of 3–40% of acetonitrile,
containing 0.1% FA (solvent B) during 30min at a ﬂow rate of 600 nL/
min. The Pa-PLA2 tryptic peptides were mass analyzed on a Synapt G2
HDMS™ mass spectrometer (Waters Corp., Manchester, UK). The MS
survey was acquired over the 200–3000m/z range at 0.5s scan time
and switched to MS/MS mode if intensity of individual ion rises above
5000 TIC. The MS/MS data was acquired over the range m/z 50 to 4500
in 0.5s scan time with a maximum of 3 ions selected from a single MS
survey and switched back to MS survey mode if intensity of individual
ion drops below 5000 TIC. Charge state peak selection was allowed only
to double and triple charge states and trap collision energy was applied
according the charge recognition. Data were processed and analyzed
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using the following tools from MassLynx software v4.1 (Waters Corp.,
Manchester, UK). Precursor mass spectra were selected using DDAtool,
processed using MaxEnt 3 algorithm and manually de novo sequenced
using PepSeq (Waters Corp., Manchester, UK).
2.7. Transcript sequencing
Total RNA was extracted from the dorsal cutaneous tissue of eight
animals using Trizol reagent (Invitrogen) and then quantiﬁed by Quant-
iT™ RiboGreen® RNA Reagent and Kit (Invitrogen) according to man-
ufacturer recommendations. Total RNA was treated with DNAse-I and
the quality and quantity of RNA were checked with a Bioanalyzer
(2100, RNA Nano 6000 Agilent). The 1st strand cDNA synthesis was
performed using 1 μg total RNA and the SMARTer™ PCR cDNA
Synthesis Kit (Clontech). After double-stranded DNA synthesis, the DNA
(∼5 μg) was nebulized to a mean fragment size of 650 bp, ligated to an
adapter using standard procedures (Margulies et al., 2005) and then
sequenced using GS-FLX Titanium (Beckman Coulter Genomics SA,
Grenoble, France). All sequencing procedures (excepted RNA extrac-
tion) were performed by 454 Life Science/Roche Company (EUA). The
search of Pa-PLA2 precursor sequence was performed across more than
600 resulting reads using Geneious software.
2.8. Multiple alignments
The Pa-PLA2 sequence was submitted and compared with sequences
described in the NCBI (National Center for Biotechnology Information)
non-redundant protein database, using BLASTp (Basic Local Alignment
Search Tool_protein). The alignment was performed with sequences
above 50% of identity, using BioEdit Sequence Alignment Editor soft-
ware, version 7.2.5.
2.9. LC-MS and MALDI-TOF-MS free N-glycan analysis
Denatured/alkylated Pa-PLA2 was treated with PNGase F overnight
to release the N-glycans. Free N-glycans were puriﬁed by Solid Phase
Extraction (SPE) using Sep Pak C18 columns, dried in a vacuum con-
centrator, permethylated with ICH3, and once again submitted to SPE in
C18 columns, according to well established methods in the literature
(Morelle and Michalski, 2007). Samples were reconstituted in 40 μL
methanol and added with 10 mM Sodium Acetate immediately before
analysis. The derivatized N-glycans were injected (6 μL of sample) in an
ekspert ultraLC 100 (Sciex, Framingham, MA, USA) coupled to a Tri-
pleTOF 5600 + mass spectrometer operating in positive mode. Chro-
matographic separation was performed in a Kinetex (2.6μ, C18, 100th,
50 × 2.1 mm) column maintained at 40 °C at a ﬂow rate of 0.2 mL/min
by applying a linear gradient of 30%–95% of 0.1% Formic acid in
MeOH for 12 min. The TripleTof 5600 + ion source operated in the
positive mode at a temperature of 650.0 °C. Mass spectrometer worked
in the High-Resolution mode with curtain gas equal to 15. The mass
range of acquisitions was between m/z 800–2000 Da. The other ac-
quiring parameters were: number of cycles = 2043; polarity = posi-
tive; period cycle time = 525 ms; pulser frequency = 13.569 kHz and
accumulation time = 500.00 ms. Mass spectrometer was calibrated
using APCI positive calibration solution before acquisitions. MS/MS
spectra were obtained using the Information Dependent Acquisition
(IDA) mode.
The native Pa-PLA2 (6.4 μM) was treated with PNGase F and PNGase
A in PBS buﬀer (pH 6.0) at 37 °C in volume ﬁnal of 100 μL for 16 h.
Buﬀered deglycosylation reaction mixtures were directly submitted to
MALDI after mixing 1:3 (v/v) with a saturated solution of 1 α-cyano-4-
hydroxycinnamic acid (CHCA). MS spectra were collected in linear
positive modes.
2.10. The sPLA2 activity test
The sPLA2 activity of Pa-PLA2 was evaluated by incubating the
glycoprotein (1.6 mM) with dimyristoylphosphatidylcholine (DMPC)
100 μM in PBS buﬀer (pH 8.5) containing Ca2+ 5mM in a ﬁnal volume
of 500 μL. The reaction tube was kept at 40 °C for 15min. An assay
using deglycosylated Pa-PLA2 (6.4 μM) in non-denaturing conditions
was carried out in the same way with a modiﬁcation (pH 6.5, volume
ﬁnal of 100 μL). Assays were performed in triplicates using Bothrops
moojeni (jararaca snake) venom (1.6 mM) as positive control and then
analyzed by MALDI-TOF/TOF MS as previously described. Samples
were mixed 1:3 (v/v) with a saturated solution of 2,5-dihydroxybenzoic
acid (DHB) and spectra were acquired in positive and reﬂector mode.
2.11. Pa-PLA2 molecular modeling
Molecular modeling was done using Schrödinger biologics suite
release 2018-3. The mature primary sequence of Pa-PLA2 was loaded
into multiple sequence viewer of Bioluminate v3.2 software and
homology model was build using consensus alignment of the following
PLAs tridimensional structures: 1JIA, 4HG9, 5WZO, 1C1J, 5WZM,
1VAP, 1U73, 5G3N, 1POE, 1RGB, 2I0U, 1OQS, 2H4C, 1VIP
(Supplementary Fig. S1). Further model adjustments were performed
manually, disulﬁde bridges were ﬁxed and one calcium ion was added
and the resulting model was submitted to molecular dynamics using
NAMD (Phillips et al., 2005). Brieﬂy, the 3D model was solvated in a
droplet water sphere using NaCl as counter ions to equilibrate system
charges. The total system energy was minimized using OPLS force ﬁeld
until the root mean square deviation (RMSD) dropped below 0.1 kcal/
mol/A (Zhao et al., 1998). This system was then equilibrated for 100ps
and molecular dynamics were performed for 1 ns at 300k for both
conditions. The ﬁnal structure from the trajectory was energy mini-
mized and water with more than 4Å away from the molecule was re-
moved. The amino acid side chains and loop reﬁnements were done and
searches for reactive residues were performed using software tools from
Schrödinger biologics suite.
3. Results
3.1. Fractionation of the cutaneous secretion of Pithecopus azureus
Reverse-phase liquid chromatography of the crude skin secretion of
Pithecopus azureus yielded not only the separation and identiﬁcation of
several compounds previously described by our group (Batista et al.,
1999; Brand et al., 2002, 2006) but also a large, unresolved and het-
erogeneous fraction (G04) eluted between 41 and 45min retention
times, where phospholipase A2 activity was originally detected
(Fig. 1A). The compounds obtained in the fraction G04 were submitted
to further separation steps resulting in 15 fractions (Fig. 1B) and a
major, highly homogeneous component showing phospholipase A2 ac-
tivity was isolated and named Pa-PLA2 (Fig. 1C), respectively.
3.2. Molecular mass investigations
The protein Pa-PLA2 was ﬁrstly mass analyzed by MALDI-TOF/MS
under linear mode and the ion corresponding to [M +
H]+=15462.44 Da was detected. Other ions from Pa-PLA2 with dif-
ferent charge states, such as [M + 2H]2+ = 7731.82 Da and
[M + 3H]3+=5154.75 Da, were also observed (Supplementary Fig.
S2). The major component present in the most intense chromatographic
fraction displayed in Fig. 1 C was mass analyzed by high resolution ESI-
QTOF/MS. This experiment revealed a classical protein glycosylation
proﬁle (Morelle and Michalski, 2007) that was conﬁrmed by the well
resolved series of 162 Da mass increment as shown in Fig. 2A. The
monoisotopic mass of the most intensely detected ion related to gly-
cosylated Pa-PLA2 was found to be [M+10H]10+=1578.593 Da that
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corresponds to a deconvoluted molecular mass of 15775.930 Da, as
shown in Fig. 2B. The low intensity ions detected suggest the presence
of minor isoforms of the same polypeptide with a similar glycosylation
pattern.
The monoisotopic mass value of the deglycosylated Pa-PLA2 was
also determined by ESI-QTOF/MS as 14317.424 Da (Fig. 3).
3.3. Phospholipase activity test
Qualitative phospholipase activity of Pa-PLA2 was determined by
the direct incubation of buﬀered samples of the native glycosylated
enzyme with the phospholipid DMPC ([M + H]+=678.50 Da). The
resulting products of this incubation under MALDI-TOF/MS mass ana-
lyses yielded three ions that conﬁrmed PLA2 activity on DMPC: a) [M+
H]+ = 468.3 Da, [M + Na]+ = 490.3 Da and [M + K]+=506.3 Da
corresponding to the lysophosphatidic acid (Fig. 4A and B) and b) [M+
Na]+= 431.2 Da corresponds to the lysophosphatidic acid with a loss
of the methylamine group by a heterolytic cleavage in the mass spec-
trometer, whereas the ions m/z 426.0 Da, 438.1 Da, 445.0 Da and
452.1 were not identiﬁed (Insert Fig. 4A). Identical components were
obtained when samples of DMPC were incubated with aliquots of lyo-
philized venom of B. moojeni under the same experimental conditions
(Fig. 4B). Similar results were also observed for the deglycosylated
enzyme, suggesting that the catalytic activity of Pa-PLA2 qualitatively
equivalent to its glycosylated form (data not shown).
3.4. Identiﬁcation and characterization of N-glycans from Pa-PLA2
The LC-MS/MS analysis of N-glycans released from denatured and
S-alkylated Pa-PLA2 after the treatment with PNGase F revealed a
number of fractions and molecules eluting in diﬀerent retention times
(Fig. 5 and Supplementary Fig. S3). Among them, the MS/MS spectra of
the ions [M + Na]+ = 763.376 Da, [M + Na]+ = 967.482 Da and [M
+ Na]+=1171.582 Da indicate the presence of the glycan moieties
GlcNAc2Man, GlcNAc2Man2, GlcNAc2Man3, respectively. MS spectra
were acquired for two other ions, [M + Na]+ = 1375.681 Da and [M
+ Na]+=1579.783 Da, consistent with the composition GlcNAc2Man4
and GlcNAc2Man5 (Fig. 6A e B), two other mannose-rich type glycans.
However, due to low signal/noise ratio, MS/MS spectra were not ob-
tained for these species and their identiﬁcations were assumed based on
the mass accuracy of the MS measurements alone. It is noteworthy that
more than one retention time were observed for each N-glycan in MS
mode (Supplementary Fig. S3), suggesting the existence of structural
isomers for each elucidated glycan composition.
Figure 1. Chromatographic steps of Pa-PLA2 isolation. On top, (A) shows the
reverse-phase HPLC semi-preparative proﬁle of the crude skin secretion of
Pithecopus azureus. Below, the chromatograms of the two additional separation
steps obtained from the G04 fraction showing (B) heterogeneous Pa-PLA2
fraction and (C) homogeneous fraction of Pa-PLA2 eluted at 44% acetonitrile
gradient.
Fig. 2. Monoisotopic mass spectra of isolated Pa-PLA2 analyzed by ESI-QTOF/
MS. (A) Ion cluster [M + 10H]10+ showing a mass increment of 16.2 Da
(162 Da) correspondent to the molecular mass value of a hexose residue. (B)
Detailed mass range showing the monoisotopic mass proﬁle of the most intense
signals related to the glycosylated Pa-PLA2 ions.
Fig. 3. Detailed mass spectrum range showing the monoisotopic ion cluster
[M + 11H]11+ of the deglycosylated Pa-PLA2 obtained by ESI-TOF/MS.
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3.5. Determination of the primary structure of Pa-PLA2
Using MALDI in source decay fragmentation technique it was pos-
sible to unveil 41 residues that constitute the N-terminal portion of the
native Pa-PLA2 (Fig. 7). The complete sequence of the N-terminal re-
gion of the mature Pa-PLA2 was determined by the de novo sequencing
of peptides obtained from tryptic proteolysis of the denatured and S-
alkylated Pa-PLA2 (Table 1, Fragments 1 and 2). Seven other tryptic
fragments from Pa-PLA2 were obtained and sequenced (Table 1, Frag-
ments 3, 4, 5, 6, 7, 8 and 9). The complete primary structure of the
mature Pa-PLA2 was unequivocally determined by the summation of
cDNA, accurate mass spectrometric and MS fragmentation data (Fig. 8).
The MS/MS spectra of fragments 6 and 7 (Table 1) could not be ac-
quired and their identities were conﬁrmed by cDNA sequencing data
(Supplementary Fig. S4; Fig. 8). The primary structure of Pa-PLA2 was
shown to have 14 cysteine residues involved in seven disulﬁde bonds.
Figure 4. MALDI-TOF mass spectrometry analyses of the phospholipase cata-
lytic products of DMPC ([M + H]+=678.50 Da) after the incubation with Pa-
PLA2 in PBS buﬀer. (A) Mass spectrum showing the hydrolyzed DMPC products
after 15min incubation with Pa-PLA2. (B) Mass spectrum showing the hydro-
lyzed DMPC products after 15min incubation with B. moojeni venom (positive
control), also indicating similar the PLA2 cleavage at the sn-2 position of DMPC
as above. (C) Mass spectrum showing the ions [M+H]+= 678.5 Da and [M+
Na]+=700.5 Da corresponding to DMPC intact molecule in the absence of
PLA2 activity (negative control).
Fig. 5. Identiﬁcation and structural characterization of the N-glycans released
from the Pa-PLA2 treated with PNGase F. MS/MS spectra of the precursors ions
[M + Na]+ = 763.376 Da (A), [M + Na]+ = 967.482 Da (B) and [M +
Na]+=1171.582 Da (C), corresponding to the glycan moieties GlcNAc2Man,
GlcNAc2Man2, GlcNAc2Man3, respectively.
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Searches on NCBI non-redundant protein data bank indicated that the
Pa-PLA2 primary structure share signiﬁcant degrees of amino acid
identity with several proteins belonging to group II phospholipase A2.
Among them, those with the highest identities (≥50%) were the ones
found in the viperid group of PLA2's sequences (Supplementary Fig. S5).
Once the primary structure of the Pa-PLA2 protein was obtained
(Fig. 8), the presence of two possible glycosylation sites in the Pa-PLA2
polypeptide chain (N67 and N108) was inferred using a glycosylation
prediction algorithm (NetNGlyc 1.0 Server) and by mass spectrometric
analyses of the protein before and after deglycosylation under non-
denaturing conditions (Fig. 9). Additional conﬁrmation of the about
glycosylation sites was obtained by MS/MS experiments on tryptic
glycopeptides, more speciﬁcally, fragments 8 and 9 (Table 1), which
revealed molecular mass values corresponding to GlcNAc2Man5 and
GlcNAc2Man3 moieties, respectively (Supplementary Figs. S6 and S7).
3.6. Molecular modeling
The quality report of the Pa-PLA2 molecular model shows only 6 and
18 residues in disallowed and allowed regions of the Ramachandran
plot respectively. All these residues are located in loop section and are
in a solvent exposed position (Supplementary Fig. S8). No steric clashes
were detected. Pa-PLA2 primary sequence shows 60% of similarity with
PLA2 found in the venom of Agkistrodon halys (Ah-PLA) (PDB:1JIA)
(Zhao et al., 1998) and demonstrate a RMSD-Cα value of 6.44Å. This
value is coherent with the large ﬂexible loop regions present in both
structures (Fig. 10A), and the ﬁnal result of Pa-PLA2 obtained after the
submission of this molecule to molecular dynamics that creates a more
relaxed structure compared to the Ah-PLA crystal.
The Pa-PLA2 tridimensional structure is constituted of three helix
regions, helix 1 (He1) from amino acid residue Phe3 to Thr13, helix 2
(He2) from Asp41 to Ser55 and helix 3 (He3) from Cys85 to Gln102,
one β-wing (Bw1) from amino acid residue Asn67 to Val78 and 5 loops
(Lo), Lo1 from Gly14 to Ile40, Lo2 from Ala56 to Tyr66, Lo3 from Ile71
to Asn74, Lo4 from Glu79 to Gly84 and Lo5 from residue His103 to
Asn130 (Supplementary Fig. S1). Seven disulﬁde bonds stabilize im-
portant regions of the Pa-PLA2: Cys56-Cys85, Cys50-Cys92 and Cys43-
Cys99 preserve He2 and He3 structures that contain the catalytic
pocket, Cys77-Cys90 restrain Bw1 to He3 and the remaining disulﬁde
bonds Cys26-Cys121 and Cys49-Cys128 locks loop Lo5 to both He2 and
Lo1 while Cys28-Cys44 locks Lo1 to He2 forcing a portion of Lo1
(Gly29 to Ala39) to shape into a pocket where a calcium ion is mounted
in place (Fig. 10B). Additionally, Pa-PLA2 present two possible N-Gly-
cosylation sites in residues Asn67 located in the beginning of Bw1 and
Asn108 in the middle of Lo5. One N-Glycosylation site is found in Ah-
PLA in residue Asn70 set in Lo3 (Fig. 10A).
Fig. 6. Identiﬁcation of the N-glycans released from the Pa-PLA2 treated with
PNGase F. (A) MS spectra showing ions [M + Na]+ = 1375.681 Da and (B) [M
+ Na]+=1579.783 Da, which are inferred to be related to glycan moieties
GlcNAc2Man4 and GlcNAc2Man5, respectively.
Fig. 7. Mass spectrum of the native Pa-PLA2 analysis
with the C-ions series assigned, corresponding to an
internal fragment composed by 41 amino acid re-
sidues of the intact protein obtained by source decay
(ISD) fragmentation method. The isobaric amino
acids (K/Q and L/I) appear alternatively represented
due a technical limitation to distinguish between
them.
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The calcium-binding loop is formed by a metal interaction from
Ca2+ ion with Asp48 side chain and carbonyl oxygens from Tyr27,
Gly29, Gly31 and four water molecules. Pa-PLA2 active site dyad is very
conserved compared to other PLA2s (Supplementary Fig. S1).
In accordance to Verheij et al. (1980) that proposed a catalytic
mechanism analogous to serine proteases (where the water molecule
performs a nucleophilic attack to the lipid ester), the Pa-PLA2 model
presents the same structural and functional features, i.e., the imidazole
ring of His47 picks up a proton from this water molecule powering the
reaction. This proton is donated to alkoxy oxygen, throws a proton
transfer from Asp93 to His47, thus ﬁnalizing the hydrolytic reaction.
The Ca2+ ion binds to the negative charge of phosphate exposing the
susceptible ester bond to the nucleophile.
4. Discussion
To our best knowledge, there have being only few studies reporting
PLA2 activity found in the cutaneous secretion of anurans (Conceição
et al., 2007; Martins et al., 2007) some personal communications on
similar occurrence in related species and a predicted amino acid se-
quence of this enzyme, based on genomic information of Xenopus tro-
picalis (NCBI, 2016), without any experimental evidence to support its
actual presence and activity on the skin of that speciﬁc animal. The
present work describes the identiﬁcation, characterization and primary
structure of a glycosylated Phospholipase A2 (Pa-PLA2) isolated from
the cutaneous secretion of Pithecopus azureus. The Pa-PLA2 polypeptide
chain is composed of 125 amino acid residues and has a monoisotopic
molecular mass of 14317.424 Da, determined after deglycosylation.
The Pa-PLA2 molecular model opened a substantial possibility to
further investigations on the actual structural and functional simila-
rities involving this amphibian skin secreted enzyme and other phos-
pholipases A2, in particular those from reptiles (Crotalinae and
Viperinae) venoms (Dennis, 1994; Dufton and Hider, 1983; Harris and
Scott-davey, 2013; Prigent-Dachary et al., 1980; Zhao et al., 1998).
According to several structural studies (Burke and Dennis, 2009; Dennis
et al., 2011; Dufton and Hider, 1983; Harris and Scott-davey, 2013;
Schaloske and Dennis, 2006; Verheij et al., 1980), the tertiary structure
of PLA2's comprises three α-helices, a calcium-binding loop, two
Table 1
List of tryptic fragment sequences from Pa-PLA2 determined by Nano-LC-MS/MS and MALDI-TOF-MS and MS/MS data analysis. The identities of the isobaric amino
acids (K/Q and I/L) were conﬁrmed by cDNA sequencing.
Peptide Sequence [M + H]+ Exp. (ESI) [M + H]+ Exp. (MALDI) [M + H]+ Theoretical
01 SLFQFR 797.432 Da 797.540 Da 797.430 Da
02 LMINYLTGK 1052.594 Da Not detected 1052.580 Da
03 NLQCVETDTSGCPR 1636.692 Da 1636.703 Da 1636.705 Da
04 DAIDWCCQVHDCCYGR 2114.801 Da 2114.856 Da 2114.829 Da
05 LPILSHSFYGCYCGAGGSGWPK 2414.115 Da 2414.177 Da 2414.105 Da
06 RICECDRa Not detected 1008.539 Da 1008.434 Da
07 ICECDRa Not detected 852.403 Da 852.333 Da
08 GlcNAc2Man5LASICFQQHDATYNSSNLDPK 3625.522 Da Not detected 3625.536 Da
Peptide Sequence [M + 2H]2+ Exp. (ESI) [M + 2H]2+ Exp. (MALDI) [M + 2H]2+ Theoretical
09 GlcNAc2Man3MSASGCDPYFQPYNFSYINKb 1641.066 Da Not detected 1641.175 Da
a Sequences inferred from MS and cDNA.
b Partially elucidated sequence by MSMS spectra.
Fig. 8. The complete primary structure of Pa-PLA2 elucidated by cDNA sequencing, mass spectrometry and protein chemistry techniques. In italics and in one letter
code are represented the nucleic acid and the amino acid sequence, respectively. Solid lines segments in blue, red, green and pink, indicate the predicted signal
peptide region, tryptic peptides sequences determined by MS/MS and MS and N-glycosylation sites, respectively. The segment in brown indicates the C-terminal
sequence deduced from cDNA. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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antiparallel β-pleated sheets (β-wing) and a less conserved C-terminal
region, as shown in our Pa-PLA2 tridimensional model (Fig. 10). Ac-
cordingly, the Pa-PLA2 framework is stabilized by seven disulﬁde bonds
formed by highly conserved cysteine residues (Supplementary 1 and
Figure 10), which is one of the most important structural features of
group II PLA2s (Burke and Dennis, 2009; Dennis, 1994; Dufton and
Hider, 1983; Harris and Scott-davey, 2013; Phillips et al., 2005;
Prigent-Dachary et al., 1980; Sobrinho et al., 2017). Moreover, the
active site dyad (H47 e D48) of our Pa-PLA2 model is highly conserved
when compared to other group II PLA2's, which is a strong indicative of
the conserved catalytic mechanism proposed by Verheij et al. (1980).
As demonstrated here, the two putative Pa-PLA2 glycosylation sites
(N67 and N108) are located far from the catalytic site (Fig. 10), and it is
unlikely that the glycan moieties to cause any signiﬁcant steric eﬀects
on the catalytic activity of this enzyme or even on speciﬁc regions of the
interfacial recognition site (IRS) (Jain and Berg, 2006; Murakami et al.,
2007). Moreover, according to a qualitative analysis, the Pa-PLA2 en-
zymatic activity against DMPC seems to be not aﬀected by deglycosy-
lation. However, a quantitative evaluation must be carried out, since
glycosylated and deglycosylated lysosomal phospholipase A2 (hLPLA2)
were demonstrated to diﬀer in their catalytic activities (Hiraoka et al.,
2013; Solá and Griebenow, 2009). Furthermore, the glycosylation is
supposed to play a role in protein stability (Moremen et al., 2012; Solá
and Griebenow, 2009) and against proteolytic degradation (Veen et al.,
2004).
According to our mass spectrometry experiments, the form of Pa-
PLA2 with short-chain glycans exhibits a GlcNAc2Man moiety at both
sites (N67 and N108). However, enzymes with more complex mannose-
rich glycans at both N-glycosylation sites, such as GlcNAc2Man5, could
be detected, as well as other combinations of diﬀerent glycan compo-
sitions. Concerning the structures of the glycans identiﬁed in Pa-PLA2,
the detection of short chains mannose-rich, as found in insects, is no-
teworthy (Lai and Her, 2000). However, at this point of our ﬁndings,
aligned with the scarcity of information on amphibian phospholipases
Fig. 9. MALDI-TOF/MS analyses of the glycosylation proﬁle of Pa-PLA2. (A)
Linear mode mass spectrum corresponding to the MS analysis of glycosylated
Pa-PLA2 (red line) and partially deglycosylated (after 1 h of incubation with
PNGase F) (black line). (B) Linear mode mass spectrum corresponding to the MS
analysis of the totally deglycosylated Pa-PLA2 after 16 h of incubation with
PNGase F. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the Web version of this article.)
Fig. 10. Homology modeling prediction of the tridimensional structure of Pa-
PLA2. (A) Structure superposition of Pa-PLA2 model (green) with the crystal
resolved structure of Ah-PLA (blue). Asn67, Asn108 and Asn70 are the N-
Glycosylation sites found in Pa-PLA2 and Ah-PLA respectively. (B) Detailed
view of Pa-PLA2 catalytic site, showing the dyad His47, Asp93 and the water
molecule as a nucleophile. Red sphere represents Ca2+ ion. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the Web
version of this article.)
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at present, an attempt to discuss the biochemical origins or the biolo-
gical relevance of these small glycan moieties detected in the Pa-PLA2
polypeptide chain would not be more then naive speculation.
Finally, the current knowledge on phospholipases associated to
numerous physiological processes (Dennis et al., 2011) indicates that,
at the present stage of our research, it would be not more than a
speculative exercise to infer any consistent biological role played by Pa-
PLA2 in the cutaneous secretion of P. azureus. However, since Pa-PLA2
appeared to be expressed constitutively at the skin of this anuran, it
could well be linked to the maintenance of cell membrane homeostasis
on epithelial tissues and/or to the defense mechanism of P. azureus
against natural predators and pathogens. Therefore, it would be inter-
esting to evaluate the potential synergistic eﬀects involving the Pa-PLA2
and various compounds present in the skin secretion, especially the
protease inhibitors, antimicrobials and other noxious peptides
(Raaymakers et al., 2017).
5. Conclusion
The identiﬁcation and characterization of the phospholipase Pa-
PLA2 reported in this study extends a bit more our knowledge on the
complex and rich molecular composition of the skin secretion of
Pithecopus azureus. Our present ﬁndings reveal structural details of this
novel polypeptide chain and its major post-translational modiﬁcation
(glycosylation) that, in turn, may embody a substantial meaning to
what might be the real physiological role of this enzyme, especially
when one considers the kind of environmental conditions on which P.
azureus is submitted. Additionally, our data rise intriguing and more
direct questions on amphibian's glycobiology that were not recorded in
the specialized literature, so far.
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